FINNENCE ▪ THE WIRE FILE
THE WIRE · № 65058
News■ Unclear/unknown
ATI Physical Therapy Launches Innovative Online Scheduling Platform to Make Accessing Care Faster and Easier
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 12:42 UTC
LAST UPDATE2026-10-05 12:42 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Online scheduling for physical therapy reflects healthcare digitalization, but the provider is privately held.
Healthcare scheduling digitization, no public ticker
CATALYST TO WATCH
Patient volume metrics if disclosed
MAIN RISK
Private company, uninvestable directly
FULL DISPATCH
ATI Online Scheduling gives eligible patients a convenient way to schedule their first physical therapy appointment online DOWNERS GROVE, Ill., Oct. 5, 2026 /PRNewswire/ -- ATI Physical Therapy, a nationally recognized provider of outpatient physical therapy and sports medicine services,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma — Chiesi Farmaceutici S.p.A.2026-10-05 12:00 UTC
New Phase 3 trial: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma — Chiesi Farmaceutici S.p.A.2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — GL Pharm Tech Corporation2026-10-05 12:00 UTC
New Phase 3 trial: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — GL Pharm Tech Corporation2026-10-05 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.